MNKD Logo

MannKind Corporation (MNKD) 

NASDAQ
Market Cap
$2.03B
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
624 of 776
Rank in Industry
337 of 433

Largest Insider Buys in Sector

MNKD Stock Price History Chart

MNKD Stock Performance

About MannKind Corporation

MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocrinologists, and other healthcare providers for the treatment of hypothyroidism. The company has a license and collaboration agreement with United Therapeutics Corporation. It also has an agreement with …

Insider Activity of MannKind Corporation

Over the last 12 months, insiders at MannKind Corporation have bought $0 and sold $2.36M worth of MannKind Corporation stock.

On average, over the past 5 years, insiders at MannKind Corporation have bought $337,420 and sold $1.23M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 3,147 shares for transaction amount of $9,221 was made by Castagna Michael (Chief Executive Officer) on 2022‑07‑31.

List of Insider Buy and Sell Transactions, MannKind Corporation

2024-09-03SaleChief People & Workpl Officer
25,000
0.0094%
$6.26$156,500+6.74%
2024-08-30SaleChief People & Workpl Officer
80,000
0.0294%
$6.33$506,050+3.59%
2024-08-29SaleChief Executive Officer
85,106
0.0308%
$6.30$536,168+2.37%
2024-08-29SaleEVP Special Projects
5,055
0.0017%
$5.94$30,027+2.37%
2024-08-29SaleEVP Genl Counsel & Secretary
5,553
0.0019%
$5.94$32,985+2.37%
2024-07-16SaleEVP Special Projects
2,836
0.0012%
$5.93$16,817+3.33%
2024-07-16SaleEVP Genl Counsel & Secretary
3,115
0.0013%
$5.93$18,472+3.33%
2024-05-21SaleEVP Special Projects
25,952
0.0094%
$4.66$120,936+22.36%
2024-05-21SaleEVP Genl Counsel & Secretary
23,537
0.0085%
$4.66$109,682+22.36%
2024-05-13SaleEVP Special Projects
3,618
0.0013%
$4.31$15,594+29.59%
2024-05-13SaleEVP Genl Counsel & Secretary
3,047
0.0011%
$4.31$13,133+29.59%
2023-12-15SaleChief Executive Officer
90,482
0.0341%
$4.00$361,928+17.11%
2023-12-14SaleChief Executive Officer
110,000
0.0409%
$4.00$440,000+15.81%
2023-11-01SaleChief Executive Officer
10,000
0.0039%
$4.25$42,500+10.42%
2023-10-02SaleChief Executive Officer
10,000
0.0038%
$4.08$40,800+5.09%
2023-09-01SaleChief Executive Officer
10,000
0.0037%
$4.61$46,100-9.72%
2023-08-28SaleEVP Genl Counsel & Secretary
8,100
0.003%
$4.78$38,738-12.26%
2023-08-01SaleChief Executive Officer
10,000
0.0039%
$4.57$45,686-6.57%
2023-07-05SaleChief Executive Officer
5,586
0.0021%
$4.01$22,407+4.75%
2023-07-03SaleChief Executive Officer
4,414
0.0017%
$4.07$17,965+5.28%

Insider Historical Profitability

8.12%
Castagna MichaelChief Executive Officer
2294836
0.8345%
$7.372016+8.74%
Binder Steven B.EVP Special Projects
1075026
0.3909%
$7.3795+23.89%
Tross Stuart AChief People & Workpl Officer
1022191
0.3717%
$7.37122+16.1%
MANN ALFRED EChairman & CEO
74750000
27.1823%
$7.37150<0.0001%
Edstrom HakanPresident & CEO
1060302
0.3856%
$7.371015+5.87%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
BlackRock$97.97M7.9421.63M-3%-$3.03M<0.01
The Vanguard Group$68.59M5.5615.14M-0.71%-$488,782.47<0.01
State Street$54.09M4.3911.94M-7.72%-$4.53M<0.01
Nitorum Fund LP$45.66M3.710.08M-6.94%-$3.41M4.65
Avoro Capital Advisors Llc$40.77M3.319M0%+$00.49
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.